Inside Precision Medicine April 17, 2024
As it expands from oncology into autoimmune disease, Cullinan Therapeutics (formerly Cullinan Oncology) yesterday announced a $280 million private placement. The company’s lead compound is now CLN-978 for systemic lupus erythematosus (SLE), which it believes has the potential to be a safe, first-in-class, off-the-shelf, disease-modifying treatment in autoimmune diseases.
“Today’s announcements represent a major step forward for Cullinan Therapeutics…we believe that CLN-978 could offer a convenient modality and potentially disease-modifying treatment for patients with autoimmune diseases where current treatments often only address symptoms, rather than the underlying disease itself,” said Nadim Ahmed, CEO of Cullinan Therapeutics.
CLN-978 is a half-life extended, CD19xCD3 bispecific T cell engager construct, that triggers redirected lysis of CD19-expressing target cells in vitro and...
Today's Sponsors
Today's Sponsor